Skip to main content
. 2012 May 1;106(11):1779–1789. doi: 10.1038/bjc.2012.176

Figure 5.

Figure 5

 Combination therapy is more effective than either agent alone in a primary tumour. The primary ovarian xenograft HOX424 shows significantly greater growth inhibition to combined trastuzumab and pertuzumab treatment than to either agent alone. Total and phosphoprotein levels were determined by AQUA quantitative immunofluorescence of TMAs for Ki67, phospho-histone H3, p21, p27 and phospho-AKT after 24 days. *P<0.05 Student’s t-test of treatment relative to control.